Expert Interview
A Second Look: Discussing the potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Ticker(s): BBIO, PFEInstitution: Stanford
- Cardiologist and physician Scientist at Amyloid Center at major academic center with a focus on Advanced Heart Failure and Transplant Cardiology.
- Currently manages 200 patients with ATTR amyloidosis and has published numerous papers on this topic.
- Research focuses on amyloidosis, transplant immunology, mechanical circulatory support, and non-ischemic cardiomyopathies.
Roughly how many patients with amyloidosis do you currently manage?
Added By: c_adminWhat are your thoughts on the anti-wt and mt amyloid ATTR antibody approach for this indication? Is there space in the treatment paradigm for these types of approach?
Added By: c_adminAlnylam's Onpattro is also being studied for use in this population. How do you that agent being used in your practice for the cm population?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
